ICMLF - Key Persons
Dr. Hochhaus is investigator for the nilotinib, dasatinib and bosutinib phase II and phase III studies, has been participating in imatinib phase II and III studies and is conducting trials of imatinib combined with pegylated interferon alpha, lonafarnib and everolimus.
Job Titles:
- ERSAP Program Coordinator
- ERSAP Program Director
Job Titles:
- Member of the Board of Directors
- Director of the OHSU Knight Cancer Institute
Dr. Druker is director of the OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research at Oregon Health & Science University, and investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He then trained in oncology at Harvard's Dana-Farber Cancer Institute.
Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. He developed 4G10, an anti-phosphotyrosine antibody that was an essential reagent to scientists at Novartis in their kinase inhibitor drug discovery program. In collaboration with Novartis, his laboratory performed pre-clinical studies that were instrumental to the development of Gleevec (imatinib), a drug that targets the molecular defect in chronic myeloid leukemia (CML). After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML, gastrointestinal stromal tumors (GIST) and five other cancers.
His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the AACR-Richard and Hinda Rosenthal Award, the Warren Alpert Prize from Harvard Medical School, the American Society of Hematology's Dameshek Prize, the Lance Armstrong Foundation's Pioneer of Survivorship Carpe Diem Award, the American Cancer Society's Medal of Honor, the Kettering Prize from General Motors Cancer Research Foundation, the David A. Karnofsky Award from the American Society of Clinical Oncology, the Robert-Koch Award, and the 2009 Lasker-DeBakey Award for Clinical Medical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Board of Directors
Charles A. Schiffer, MD, is Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program.
Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.
Dr. Schiffer has authored and co-authored more than 300 articles and 80 book chapters on topics concerning the treatment of leukemia in adults, platelet transfusion, and granulocyte transfusion therapy, among others. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion, and reviews articles for multiple journals. Committee memberships have included Chairman of the Leukemia Committee of the Cancer and Leukemia Group B, Chairman of the Food and Drug Administration Oncologic Drug Advisory Committee, and grant reviews for the NCI and Leukemia/Lymphoma Society of America. Dr. Schiffer has been named among American Health Magazine's and Castle Connelly's "Best Doctors in America," "Best Cancer Specialists in the US." In 2006, he received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America and the Celgene Award for Career Achievement in Hematology. He has received multiple teaching awards from Wayne State University and was recently inducted into the Academy of Scholars, the highest recognition accorded to academic faculty at the University.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Co - Ordinator of the
- Professor of Internal Medicine / Department of Clinical and Biological Sciences / University of Turin / Turin, Italy
- Professor of Internal Medicine and Haematology at the University of Turin
Dr Giuseppe Saglio is Professor of Internal Medicine and Haematology at the University of Turin. He is Director of the Department of Clinical and Biological Sciences at the University of Turin and responsible for the Division of Internal Medicine and Haematology at San Luigi University Hospital. He graduated from the University of Turin in 1975. Since then he has studied Internal Medicine at the University of Turin (1975-1980), Haematology at the University of Milan (1980-1983) and Molecular Biology at the University of Leiden (1976), Inserm-Creteil, Paris (1979) and the University of California (1983).
Dr Saglio is co-ordinator of the PhD programme in Molecular Medicine and Experimental Therapy at the University of Turin, past-president of the Italian Society of Experimental Haematology (SIES) and general secretary of the IACRLRD (International Association for Comparative Research on Leukemia and Related Diseases). He has published more than 500 peer-reviewed articles in the fields of molecular pathogenesis of haematological malignancies (1986-present), molecular medicine applied to clinical medicine (1978-present) and the molecular basis of thalassemia and related haemoglobinopathies (1978-1990).
Job Titles:
- Professor & Head, Department of Medical Oncology at the Sriram Cancer Center
Dr. Hemant Malhotra is presently Professor & Head, Department of Medical Oncology at the Sriram Cancer Center of the Mahatma Gandhi College Hospital, Jaipur. Since superannuating after more than three decades of government service where he was the PHOD, Department of Medicine and Head of the division of Medical Oncology at the Birla Cancer Center, SMS Medical College, Jaipur, he now working full time at the MGMCH. The Mahatma Gandhi Medical College Hospital is 1400 bedded, one of the leading tertiary care teaching and patient care center of North India, and the largest in the private sector.
Dr. Malhotra graduated and post-graduated at the top of his batch from the SMS Medical College and after fellowships at Tata Memorial Cancer Center, Mumbai (1989 to 1991); Cornell Medical Center, New York and Memorial Sloan Kettering Cancer Center, New York, set up the Medical Oncology division in the department of Medicine at the SMS Hospital in 1991, the first in the state of Rajasthan. He also established a Bone Marrow Transplantation Unit at the SMS and his team has successfully done the first-ever autologous bone marrow transplantation in the state of Rajasthan. Regular autologous and allogeneic Stem Cell Transplantations are now being done in the unit.
Dr. Malhotra has more than three decades of treating cancer patients in the state of Rajasthan is a well-recognized and respected teacher. Many of his students are now senior medical oncologists spread all over the country and heading their own departments.
He is an internationally and nationally recognized medical oncologist and was the India, Pakistan & Bangladesh representative to the European Society for Medical Oncology (ESMO) from 2006 to 2008. He is also ESMO board certified in medical oncology. He is an advisor/consultant/referee/committee member for oncology to several Government of India bodies and head the ICMR committee for formulation of guidelines for multiple myeloma. He serves on the Specialty Expert Committee on Hematology & Oncology of the Drug Controller General of India. He has served on the National Oncology SAE Committee of the Drug Controller General of India, Government of India. He has been an invited consultant to the WHO on guideline development for bio-similar oncology molecules.
Dr. Malhotra has to his credit more than 200 international and national publications and presentations and is an office bearer and member of many international and national societies and organizations. He is the lead author of a chapter on Chronic Leukemia in the Oxford Text book of Oncology. He is the Immediate Past President of the Indian Society of Medical & Pediatric Oncology (ISMPO). He is one of the founder members & Head of
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Senior Consultant at the Hematology Department
Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic, in Barcelona, Spain, and associate professor at the University of Barcelona. His main scientific interest is the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published more than 190 articles in peer-review international journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology, Experimental Hematology, Haematologica, Cancer, Oncogene, Seminars in Oncology, and the European Journal of Haematology. In the CML field, Dr. Cervantes contributed to the elaboration of Sokal's score, is a coauthor of the publications of the IRIS study, which established imatinib as first-line treatment for CML, has participated in the introduction of the second-generation tyrosine kinase inhibitors for patients resistant to imatinib, as well as in the authorship of the European LeukemiaNet recommendations for the treatment of CML. His more recent contributions in the field of the MPNs have been the elaboration of the new prognostic classification of primary myelofibrosis on behalf of the International Working Group for Myelofibrosis Research and Treatment, as well as several studies on the role of leukocyte and platelet activation in the thrombosis of MPN patients. At local level, he is the national coordinator of the CML studies within the collaborative PETHEMA Spanish group. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for Myeloproliferative Neoplasms Research and Treatment, the European Leukemianet, and the Spanish Society of Hematology.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Scientific Advisory Committee Are
- Chairman, LeukaNET / Leukämie - Online, Germany / Co - Founder, CML Advocates Network
- Co - Founder of the European Cancer Patient Coalition
In July 2001, Jan received his diagnosis of a rare cancer, Chronic Myeloid Leukemia (CML), at a routine check-up. He then joined a phase I/II clinical trial. As hardly any information on upcoming treatments was available in the German language, he started to simplify and translate medical publications into German language. In 2002, he started to publish them by founding the online patient community Leukämie-Online (http://www.leukaemie-online.de), which is one of the most frequented patient websites on leukemia in the German speaking Internet today. Leukämie-Online became a charitable organisation in Germany in 2006, with Jan being the Chair.
In 2007, Jan has co-founded the CML Advocates Network (http://www.cmladvocates.net) together with other CML patient groups from Israel, the UK and Czech Republic. The goal of the web-based platform is to get organisations connected that are supporting patients with Chronic Myeloid Leukemia. Today, members include 57 CML groups from all continents, sharing best practice in cancer patient advocacy and campaigning for better treatment and care of CML patients world wide.
Jan is also a co-founder of the European Cancer Patient Coalition (ECPC), a board member of the European Forum for Good Clinical Practice (EFGCP), and acts on a number of advisory boards.
In the International CML Foundation (iCMLf), Jan acts as Communications Coordinator and runs the foundation's Pediatric CML program.
Job Titles:
- Member of the Board of Directors
- Chairman of the Department of Haematology
- Professor of Medicine Chair, Department of Haematology Hammersmith Hospital / Imperial College
Professor Jane Apperley is the Chair of the Department of Haematology at the Imperial College and the Chief of Service for Clinical Haematology at the Imperial College Healthcare NHS Trust in London, England. Jane Apperley served as the President of both the European Group of Blood and Marrow Transplantation and the British Society of Blood and Marrow Transplantation. She also serves on the Advisory Board of the Centre for International Blood and Marrow Transplant Research.
She qualified in Medicine from the University of Birmingham and after initial specialization in internal medicine she completed specialist training in hematology in Birmingham, London, Cambridge and Boston.
Her particular interests are the biology and management of CML, which has led to an extensive experience in stem cell transplantation and to the use of signal transduction inhibitors. Her group at the Hammersmith Hospital site has extensive experience in the use of the first- and second-generation TKI's, particularly in the areas of molecular monitoring and mechanisms of drug resistance. She has a long-standing interest in the ways in which hematologic diseases and their treatment impact fertility, pregnancy, and fetal outcome.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center
Jerald P. Radich, M.D., is a Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and is Professor of Medicine at the University of Washington. He is the Medical Director of the Research Trials Office at the FHCRC, the co-chair of Leukemia Biology for the Southwest Oncology Group, and is the co-chair of the NCI/Cooperartive Group Leukemia Steering Committee. He belongs to the National Cancer Care Network and EuroLeukemiaNet CML committees. Dr. Radich's main research interest concerns the genetics of leukemia, and the use of and development of modern molecular biology techniques towards early detection of leukemia.
For people wanting to give a donation to the iCMLf in memory of Professor John Goldman the iCMLf has established a specific fund in his honour. John had a particular passion to educate young physicians. The John Goldman Fund supports young physicians to attend and present their work at the annual John Goldman CML meeting. In 2015 physicians from Nigeria and Ukraine came to the meeting in Estoril and presented their work to the CML community.
Professor John M. Goldman has a long standing interest in the biology and therapy of chronic myeloid leukemia (CML). He was until 2004 Chairman of the Department of Haematology at Imperial College London, Director of the Leukaemia Research Fund Centre for Adult Leukaemia and Clinical Director of the Haematology Department at the Hammersmith Hospitals NHS Trust. Thereafter he took up a 2-year appointment as Fogarty Scholar at the National Institutes of Health in Bethesda USA. He is now active as Emeritus Professor of Haematology at Imperial College London and Medical Director of the Anthony Nolan Trust. He is editor of Bone Marrow Transplantation, a former editor of The Haematology Journal, and an associate editor of the European Journal of Haematology. He is also an editorial board member of numerous other journals and, during the course of his career, has published over 800 papers in peer-reviewed journals. As well as being the founding president of the British Society for Blood and Marrow Transplantation, he is a former president of the International Society for Experimental Hematology, the European Group for Blood and Marrow Transplantation and the European Hematology Association.
Professor Goldman was the first to autograft patients with CML using peripheral blood stem cells and started allogeneic stem cell transplant for CML in 1980. He pioneered the use of unrelated donors for transplanting CML patients and developed PCR technology for monitoring residual disease. He confirmed the preclinical efficacy of the original tyrosine kinase inhibitor (STI571, now imatinib) in 1997 and first used it in the clinic in 1999. Thereafter he has been involved in development of second generation TKIs, notably dasatinib and nilotinib.
Job Titles:
- Chairman
- Member of the Board of Directors
- Professor of Medicine / Chief, CML Section / Department of Leukemia
Jorge Cortes, MD, is deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston Texas where he directs the CML Program. Dr. Cortes received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, Mexico City, and has been at MD Anderson Cancer Center since 1991. Dr. Cortes, whose clinical interest focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders has authored over 400 peer-reviewed medical publications. He has received numerous awards including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr. John J. Kenny Award from The Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from The Leukemia & Lymphoma Society in 2007, and the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007. Dr. Cortes is chief editor of Current Hematological Malignancies Reports and Clinical Leukemia and serves in the Editorial Board of the Journal of Clinical Oncology, Leukemia, Clinical Cancer Research, Leukemia and Lymphoma and the American Journal of Hematology.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Leader, Myeloproliferative Neoplasms ( MPN ) Program / Memorial Sloan - Kettering Cancer Center
- Professor
Professor Michael Mauro directs the Myeloproliferative Neoplasms (MPN) Program at the Memorial Sloan-Kettering Cancer Center in New York. He received his medical degree from Dartmouth Medical School and completed his residency and fellowship training at New York-Presbyterian Hospital/Weill Cornell Medical Center. For more than a decade he worked with Dr Brian Druker at the OHSU Knight Cancer Institute in Portland, Oregon with a focus on research in CML. There he directed the CML clinical trial program and was involved in the early development and sentinel clinical study of targeted therapy for CML. His clinical focus is in CML with interest in therapy optimization, novel therapies, treatment free remission and pregnancy/fertility, as well as other myeloproliferative neoplasms, including myelofibrosis, polycythemia and thrombocytosis and less common conditions such as eosinophillic and mast cell disorders.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Scientific Advisory Committee Are
- Co - Founder of the Max Foundation
- Executive Director of the Max Foundation
Pat Garcia-Gonzalez, Executive Director of The Max Foundation, has been dedicated to improving the lives of blood cancer survivors around the world for over twelve years. A native of Argentina, Pat has a Master degree from the University of Washington and technical degree in nursing.
Pat is co-founder of The Max Foundation, an international NGO based in Edmonds, Washington, started in 1997 to connect families facing leukemia with resources for treatment access.
Under Pat's direction since 2005, The Max Foundation provides services to over 15,000 CML patients in more than 90 countries annually and has successfully started and supported local patient organizations in 12 countries.
In 2008, Pat was awarded the distinguished honor of the Golden Tennis Shoe Award from United States Senator, Patty Murray for her service and dedication to her community. She is a member of the Global Health Council and of the CML Advocates Network.
Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Job Titles:
- Member of the Scientific Advisory Committee Are
Professor Susan Branford is Head of the Leukaemia lab in the Department of Genetics and Molecular Pathology at SA Pathology.
Sue has expertise in molecular monitoring of the BCR-ABL1 gene for patients with chronic myeloid leukemia. As such she is a major contributor to International collaborative initiatives to establish guidelines and recommendations for producing reliable molecular data.
Dr Branford's research is focused on understanding the factors that predict response to tyrosine kinase inhibitor therapy and mechanisms of drug resistance.
Job Titles:
- Member of the Scientific Advisory Committee Are
Job Titles:
- Member of the Board of Directors
- Professor Timothy P. Hughes, MD, FRACP, FRCPA
Timothy P. Hughes, MD, FRACP, FRCPA, is Head of the Department of Haematology at SA Pathology, RAH site, and Consultant Haematologist at the Royal Adelaide Hospital. He is also Clinical Professor of Medicine at the University of Adelaide and holds a Practitioner Fellowship from the National Health and Medical Research Council. His clinical interests include chronic leukaemias and myeloproliferative disorders. His current research interests focus are in molecular monitoring for leukaemias, clinical resistance to targeted therapies in leukaemia and the development of assays to predict response and resistance to targeted agents. He has published over 100 articles in peer-reviewed journals. He is a member of the Haematology Society of Australia and New Zealand, for which he served as President from 2001 to 2003, and the Australasian Leukaemia and Lymphoma Group, for which he served as a Director from 1999-2004 and as Vice-Chairman in 2003-4. In 2006 Professor Hughes was awarded the RACP Eric Susman Prize for the most outstanding contribution to the knowledge of any branch of internal medicine by a member of the College of Physicians.